No, Abilify (aripiprazole) is NOT FDA-indicated for eating disorders.
Aripiprazole has no FDA approval for the treatment of anorexia nervosa, bulimia nervosa, binge-eating disorder, or any other eating disorder. The FDA-approved indications for aripiprazole include schizophrenia, bipolar disorder, major depressive disorder (as adjunctive therapy), autistic disorder (irritability), and Tourette's disorder—but eating disorders are notably absent 1.
What the Guidelines Actually Recommend
The 2023 American Psychiatric Association Practice Guideline for eating disorders provides clear, evidence-based treatment recommendations that do not include aripiprazole 2:
For Anorexia Nervosa:
- Adults: Eating disorder-focused psychotherapy (1B recommendation)
- Adolescents/emerging adults: Family-based treatment (1B recommendation)
- No medication is recommended as primary treatment
For Bulimia Nervosa:
- Adults: Cognitive-behavioral therapy PLUS fluoxetine 60 mg daily (1C recommendation)
- The guideline specifically recommends a serotonin reuptake inhibitor (fluoxetine), not aripiprazole 2
For Binge-Eating Disorder:
- First-line: Cognitive-behavioral therapy or interpersonal therapy (1C recommendation)
- Medication option: Antidepressants or lisdexamfetamine if psychotherapy fails or patient prefers medication (2C suggestion)
- Again, aripiprazole is not mentioned 2
The Research Evidence: Promising but Insufficient
While aripiprazole is not indicated, there is emerging research suggesting potential benefit, particularly in anorexia nervosa:
- A 2025 retrospective study in adolescents showed aripiprazole (mean dose 1.9-2.8 mg/day) reduced food avoidant behaviors and improved weight restoration 3
- A 2017 adolescent study found aripiprazole associated with greater BMI increase during treatment 4
- Multiple case reports and small series suggest improvements in eating-related obsessions, anxiety around eating, and weight restoration 5, 6, 7
However, these are all retrospective reviews, case series, or open-label studies—not randomized controlled trials. The highest quality evidence (the 2023 APA guidelines) does not support its use 2.
Critical Safety Considerations
The FDA label reveals important adverse effects that are particularly concerning in eating disorder populations 1:
- Weight gain (3% of patients in general populations, but potentially higher in eating disorder contexts)
- Metabolic effects including increased appetite
- Extrapyramidal symptoms (akathisia in 25% of adjunctive MDD patients)
- Impulsive-compulsive behaviors including problem eating, as documented in a 2024 systematic review 8
Common pitfall: Using aripiprazole off-label without recognizing that it can paradoxically worsen eating behaviors through impulsive-compulsive side effects in some patients.
Clinical Bottom Line
Do not prescribe aripiprazole for eating disorders as a primary or routine intervention. The evidence-based approach prioritizes:
- Psychotherapy first: Family-based treatment for adolescents, eating disorder-focused CBT for adults
- Fluoxetine 60 mg for bulimia nervosa (the only medication with a strong recommendation)
- Antidepressants or lisdexamfetamine for binge-eating disorder if psychotherapy inadequate
- Multidisciplinary team including medical, psychiatric, psychological, and nutritional expertise 2
If considering aripiprazole off-label in treatment-refractory anorexia nervosa with severe eating-related obsessions, use only:
- After psychotherapy has been optimized
- At low doses (2-5 mg/day based on research data)
- With close monitoring for weight gain, metabolic effects, and paradoxical impulsive eating
- With informed consent about off-label use and limited evidence
The lack of FDA indication reflects the lack of high-quality evidence supporting its use, and guideline-concordant care should be prioritized for optimal patient outcomes.